Pro-Dex (PDEX) Stock Forecast & Price Target

Pro-Dex is supported by a durable growth profile, with revenue rising 17% in FY26 to $76 million in management’s updated estimate and EPS improving to $3.94, while Q4 FY2026 revenue of $20.4 million and EPS of $0.86 both exceeded expectations. Its outlook is further strengthened by expanding gross margin to 35% from 20% on better product mix and operating leverage, plus a proprietary niche in regulated medical contract manufacturing that benefits from new device wins and private label investment. The APM acquisition should add automation, machining capacity, and diversification, helping reduce customer concentration risk while supporting FY27 and FY28 revenue estimates of $83 million and $87 million.

Pro-Dex is facing a weakening fundamental backdrop because its 15% revenue growth was driven by new medical device product sales while lower repairs revenue offset the gain, suggesting an uneven and potentially less durable mix. Gross margin compression to 31% from 33% year over year indicates profitability pressure from an unfavorable product mix, which can limit operating leverage even if top-line growth persists. Beyond company-specific issues, the outlook is clouded by competition and changing macroeconomic factors, alongside volatile investor and consumer sentiment toward technology manufacturing stocks.